Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up.

The impact of statin use on localized prostate cancer (PCa) remains controversial, especially for patients treated with radiation therapy. We assessed the impact of statin use on biochemical recurrence (BCR) in patients treated for PCa with different modalities of radiation therapy. We evaluated 3555 patients undergoing radiation therapy between January 2001 and January 2022. The impact of statin use on BCR was analyzed for three treatment groups: external beam radiotherapy (EBRT), low-dose-rate seed brachytherapy (LDR), and EBRT plus high-dose-rate brachytherapy (EBRT + HDR). Median follow-up was 52 months among 1208 patients treated with EBRT, 1679 patients treated with LDR, and 599 patients treated with EBRT + HDR. A total of 1544 (43%) patients were taking a statin at the time of treatment, and 497 (14%) patients were in the D'Amico high-risk group. Only intermediate-risk patients treated with LDR fared better with statin use in univariate analysis (p = 0.025). This association was not significant in multivariate analysis (HR 0.44, 95% CI 0.18-1.10, p = 0.06). Statin use was not associated with a reduced risk of BCR in patients treated with radiation therapy. In the era of precision medicine, further investigation is needed to assess the benefit of statins in well-defined patients.

Cancers. 2022 Jul 24*** epublish ***

Kevin Kaulanjan, Danny Lavigne, Fred Saad, Pierre I Karakiewicz, Rocco Simone Flammia, Luis Alex Kluth, Philipp Mandel, Felix K-H Chun, Daniel Taussky, Benedikt Hoeh

Institut du Cancer de Montréal (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC H2X 0A9, Canada., Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal, Montréal, QC H2X 0A9, Canada., Department of Surgery, Division of Urology, Centre hospitalier de l'Université de Montréal, Montréal, QC H2X 0A9, Canada., Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H2X 0A9, Canada., Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60318 Frankfurt am Main, Germany.

email news signup